Merck KGaA Goes On A Shopping Spree

5 October 1997

October has already seen three company acquisitions by Germany's MerckKGaA, which the firm says are part of its ongoing strategy in the pharmaceuticals business. The purchase prices of the three firms are not being disclosed.

The first is Wolfrastshausen, Bavaria-based generics drugmaker Durachemie GmbH, which specializes in marketing and distributing generic drug products. Durachemie's sales last year reached 95 million Deutschemarks ($53.9 million), made up from 70 or so products in high-volume indications such as the cardiovascular, central nervous system and lipid metabolism areas.

Together with Merck Generika GmbH, which was founded in 1996, this makes Merck one of Germany's top 10 suppliers of generics products, and the only one with a worldwide generics business. Merck's total generics sales in 1996 amounted to 620 million marks. For first-half 1997, generics revenues were 500 million marks, showing a 71.4% increase on first-half 1996.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight